Chiral Chelating Diaminocarbene Ligands
ica gel (dichloromethane/acetone, 9:1) to afford the expected azol-
ium salt.
3,4-Dihydro-5-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-2-(naphth-1-
ylmethyl)-1H-imidazolin-1-ium Hexafluorophosphate (6d): White
solid (270 mg, 55% yield). [α]2D0 = 2 (c = 0.1, acetone); m.p. 62 °C.
1H NMR (400 MHz, CD2Cl2): δ = 7.86 (m, 3 H, Har), 7.81 (s, 1
General Procedure for the Synthesis of Hydroxyaryl-Imidazolinium
Salts 8, 9: To a solution of diamine (1 equiv.) in dry diethyl ether
(5 mL/mmol) was added dropwise, at 0 °C, a 2 anhydrous HCl/
MeOH solution (2 equiv.). A white precipitate was rapidly formed.
After 10 min of strirring, the solvent was evaporated to afford the
corresponding chlorhydrate of diamine. This salt was dissolved in
dry toluene (3 mL/mmol), and trimethyl orthoformate (10 equiv.)
was added. The reaction mixture was stirred for 90 min at 100 °C.
After being cooling to room temperature, the solvents were evapo-
rated in vacuo, and the imidazolinium chloride was dissolved in
distilled water. The aqueous layer was washed with ethyl acetate
before with the addition of potassium hexafluorophosphate
(1.3 equiv.). After 20 min of stirring at room temperature, the imid-
azolinium salt was extracted with dichloromethane. The organic
layer was washed with brine, dried with magnesium sulfate and
concentrated under reduced pressure. The resulting crude product
was purified by flash chromatography on silica gel (dichlorometh-
ane/acetone, 9:1) to afford the expected azolium salt.
3
4
H, H-19), 7.56 (ddd, 3J = 6.9 Hz, J = 8.4 Hz, J = 1.5 Hz, 1 H,
3
3
4
Har), 7.50 (ddd, J = 6.9 Hz, J = 8.0 Hz, J = 1.2 Hz, 1 H, Har),
7.45 (m, 2 H, Har), 4.98 (s, 2 H, H-1), 3.82 (m, 2 H, H-12), 3.76
2
3
(m, 2 H, H-13), 3.67 (m, 1 H, H-14), 3.59 (dd, J = 12.0 Hz, J =
2
3
3.5 Hz, 1 H, H-15), 3.44 (dd, J = 12.0 Hz, J = 8.7 Hz, 1 H, H-
15), 2.68 (s broad, 1 H, OH), 1.40 (m, 2 H, H-16), 1.21 (m, 1 H,
3
3
H-17), 0.83 (d, J = 6.5 Hz, 3 H, H-18), 0.80 (d, J = 6.5 Hz, 3 H,
H-18) ppm. 13C NMR (100 MHz, CD2Cl2): δ = 157.9 (1 CH, C-
19), 134.8 (1 C, Car), 131.8 (1 C, Car), 131.2 (1 C, Car), 130.0 (1
CH, Car), 129.5 (1 CH, Car), 128.3 (1 CH, Car), 128.1 (1 CH, Car),
127.4 (1 CH, Car), 126.3 (1 CH, Car), 123.1 (1 CH, Car), 61.8 (1
CH2, C-15), 60.0 (1 CH, C-14), 50.8 (1 CH2, C-1), 48.9 (1 CH2, C-
12), 46.0 (1 CH2, C-13), 37.7 (1 CH2, C-16), 25.4 (1 CH, C-17),
23.1 (1 CH3, C-18), 22.3 (1 CH3, C-18) ppm. 31P NMR (162 MHz,
CD2Cl2): δ = –144.3 (sept, 1J = 712.4 Hz, 1 P) ppm. 19F NMR
1
(376 MHz, CD2Cl2): δ = –71.4 (d, J = 712.4 Hz, 6 F) ppm.
3,4-Dihydro-5-[(1S)-1-(hydroxymethyl)-2-dimethylpropyl]-2-[(1R)-1-
(naphth-1-yl)ethyl]-1H-imidazolin-1-ium Hexafluorophosphate (6f):
White solid (667 mg, 42% yield). [α]2D0 = –41.0 (c = 1, acetone);
m.p. 65 °C. 1H NMR (400 MHz, CD2Cl2): δ = 7.87 (m, 4 H, H-20,
Selected Salts
(4S)-1-(2-tert-Butylphenyl)-4,5-dihydro-3-(2-hydroxyethyl)-4-isopro-
pyl-1H-imidazol-3-ium Bis(trifluoromethylsulfonyl)azanide (5e):
Slightly yellow oil (352 mg, 62%). [α]2D0 = +16.8 (c = 1, chloroform).
3
Har), 7.52 (m, 3 H, Har), 7.40 (d, J = 6.4 Hz, 1 H, Har), 5.55 (q, J
= 6.8 Hz, 1 H, H-1), 3.82 (m, 6 H, H-13, H-14, H-15, H-16), 3.44
(dd, 2J = 10.4 Hz, 3J = 3.6 Hz, 1 H, H-16), 2.45 (s broad, 1 H,
OH), 1.82 (d, 3J = 6.8 Hz, 3 H, H-12), 0.90 (s, 9 H, H-18) ppm.
13C NMR (100 MHz, CD2Cl2): δ = 157.87 (CH, C-20), 134.56 (C,
Car), 132.51 (C, Car), 130.75 (C, Car), 130.41 (CH, Car), 129.78 (CH,
Car), 127.91 (CH, Car), 126.86 (CH, Car), 125.85 (CH, Car), 124.50
(CH, Car), 122.05 (CH, Car), 70.75 (CH, C-15), 57.91 (CH2, C-16),
54.82 (CH, C-1), 48.13 (CH2, C-13), 47.56 (CH2, C-14), 33.82 (C,
C-17), 27.44 (CH3, C-18), 19.36 (CH3, C-12) ppm. 31P NMR
3
1H NMR (400 MHz, CDCl3): δ = 8.08 (s, 1 H, H-13), 7.55 (d, J
3
3
= 7.4 Hz, 1 H, H-9), 7.43 (t, J = 7.4 Hz, 1 H, H-7), 7.32 (t, J =
3
3
7.4 Hz, 1 H, H-8), 7.18 (d, J = 7.4 Hz, 1 H, H-6), 4.62 (dt, J =
4.8, 11.8 Hz, 1 H, H-2), 4.30 (t, J = 11.8 Hz, 1 H, H-1), 3.95 (t,
3
3J = 11.8 Hz, 1 H, H-1Ј), 3.85 (m, 3 H, H-14, H-15), 3.64 (m, 1 H,
H-14Ј), 2.39 (m, 1 H, H-3), 1.39 (s, 9 H, H-12), 1.07 (d, 3J = 7.0 Hz,
3 H, H-4), 1.01 (d, 3J = 7.0 Hz, 3 H, H-4Ј) ppm. 13C NMR
(100 MHz, CDCl3): δ = 159.2 (1 C, C-13), 147.4 (1 C, C-5), 134.1
(1 C, C-10), 130.7 (1 C, C-9), 129.5 (1 C, C-7), 128.8 (1 C, C-8),
1
(162 MHz, CD2Cl2): δ = –144 (sept, J = 710.3 Hz, 1 P) ppm. 19F
1
128.1 (1 C, C-6), 119.1 (q, JC,F = 321.2 Hz, 1 C), 65.0 (1 C, C-2),
1
NMR (376 MHz, CD2Cl2): δ = –72.5 (d, J = 710.3 Hz, 6 F) ppm.
57.3 (1 C, C-1), 54.8 (1 C, C-15), 47.7 (1 C, C-14), 35.6 (1 C, C-
HRMS (Maldi/TOF): calcd. for C21H29N2O [M]+ 325.2280; found
325.228. C21H29F6N2OP (470.43): calcd. C 53.62, H 6.21, N 5.95;
found C 53.06, H 6.24, N 5.67.
11), 31.7 (3 C, C-12), 26.7 (1 C, C-3), 17.7 (1 C, C-4), 14.4 (1 C,
1
C-4Ј) ppm. 19F NMR (376 MHz, CDCl3): δ = –73.0 (d, JF,C
=
321.2 Hz, 6 F) ppm. HRMS calcd. for C18H29N2O [M]+ 289.2280;
found 289.2280.
2-Cyclohexyl-5-[(1S)-1-(hydroxymethyl)-3-methylpropyl]-1H-benz-
imidazol-1-ium Hexafluorophosphate (7a): White solid (500 mg,
39% yield). [α]2D0 = –7.0 (c = 1, acetone); m.p. 132 °C. 1H NMR
(400 MHz, CD2Cl2): δ = 8.94 (s, 1 H, H-17), 7.76 (m, 2 H, Har),
3,4-Dihydro-5-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-2-[(1R)-1-
(naphth-1-yl)ethyl]-1H-imidazolin-1-ium Hexafluorophosphate (6b):
White solid (160 mg, 65% yield). [α]2D0 = –44.0 (c = 1, acetone);
3
3
7.64 (m, 2 H, Har), 4.47 (tt, J = 3.7 Hz, J = 12.0 Hz, 1 H, H-1),
1
2
3
3
m.p. 101 °C. H NMR (400 MHz, CD2Cl2): δ = 7.99 (m, 4 H, H-
4.34 (ddd, J = 6.3 Hz, J = 9.7 Hz, J = 3.2 Hz, 1 H, H-14), 4.16
3
4
20, Har), 7.68 (td, J = 7.6 Hz, J = 1.6 Hz, 1 H, Har), 7.61 (m, 2
(ddd, 2J = 6.3 Hz, 3J = 11.6 Hz, 3J = 4.9 Hz, 1 H, H-14), 3.99 (ddd,
3
3
3
H, Har), 7.53 (m, 1 H, Har), 5.63 (q, J = 6.8 Hz, 1 H, H-1), 3.89
3J = 12.4 Hz, J = 4.9 Hz, J = 3.2 Hz, 1 H, H-13), 2.77 (m, 1 H,
(m, 4 H, H-13, H-14), 3.75 (dd, 2J = 12.0 Hz, J = 3.6 Hz, 1 H, H-
OH), 2.45 (m, 1 H, H-15), 2.23 (d, J = 12.2 Hz, 2 H, Hcy), 1.88
3
3
16), 3.56 (dd, 2J = 12.0, 3J = 8.8 Hz, 1 H, H-16), 1.93 (d, 3J = (m, 4 H, Hcy), 1.73 (d, J = 12.8 Hz, 1 H, Hcy), 1.56 (m, 2 H, Hcy),
3
6.8 Hz, 3 H, H-12), 1.53 (m, 3 H, H-15, H-17), 1.36 (m, 1 H, H- 1.34 (dt, 2J = 13.2 Hz, 3J = 3.6 Hz, 1 H, Hcy), 1.27 (dt, 2J =
3
3
3
3
18), 0.98 (d, J = 6.8 Hz, 3 H, H-19), 0.92 (d, J = 6.4 Hz, 3 H, H-
19) ppm. 13C NMR (100 MHz, CD2Cl2): δ = 156.7 (1 CH, C-20),
134.6 (1 C, Car), 132.6 (1 C, Car), 130.8 (1 C, Car), 130.4 (1 CH,
Car), 129.8 (1 CH, Car), 127.9 (1 CH, Car), 126.8 (1 CH, Car), 125.9
13.2 Hz, J = 3.6 Hz, 1 H, Hcy), 1.10 (d, J = 6.6 Hz, 3 H, H-16),
0.74 (d, 3J = 6.7 Hz, 3 H, H-16) ppm. 13C NMR (100 MHz,
CD2Cl2): δ = 137.0 (1 CH, C-17), 131.4 (1 C, Car), 130.0 (1 C, Car),
126.7 (1 CH, Car), 126.5 (1 CH, Car), 113.1 (1 CH, Car), 112.8 (1
(1 CH, Car), 124.6 (1 CH, Car), 122.1 (1 CH, Car), 61.4 (1 CH2, C- CH, Car), 66.5 (1 CH, C-13), 60.1 (1 CH2, C-14), 58.2 (1 CH, C-
16), 59.8 (1 CH, C-15), 54.8 (1 CH, C-1), 47.4 (1 CH2, C-13), 45.1 1), 31.7 (1 CH2, Ccy), 31.6 (1 CH2, Ccy), 28.9 (1 CH, C-15), 24.6
(1 CH2, C-14), 36.9 (1 CH2, C-17), 25.1 (1 CH, C-18), 22.7 (1 CH3, (1CH2, Ccy), 24.5 (1 CH2, Ccy), 24.0, (1 CH2, Ccy), 18.6 (1 CH3, C-
C-19), 21.9 (1 CH3, C-19), 19.4 (1 CH3, C-12) ppm. 31P NMR 16), 18.5 (1 CH3, C-16) ppm. 31P NMR (162 MHz, CD2Cl2): δ =
(162 MHz, CD2Cl2): δ = –143.1 (sept, 1 P, 1J = 711.5 Hz) ppm. 19
F
–144.4 (sept, 1J = 710.6 Hz, 1 P) ppm. 19F NMR (376 MHz,
1
1
NMR (376 MHz, CD2Cl2): δ = –73.1 (d, 6 F, J = 711.5 Hz) ppm. CD2Cl2): δ = –72.5 (d, 6 F, J = 710.6 Hz). HRMS (Maldi/TOF):
HRMS (Maldi/TOF): calcd. for C21H29N2O [M]+ 325.2280; found
calcd. for C1 8 H2 7 N2 O [M]+ 287.2123, found 287.2122.
325.2287. C21H29F6N2OP (470.43): calcd. C 53.62, H 6.21, N 5.95; C18H27F6N2OP (432.38): calcd. C 50.00, H 6.29, N 6.48; found C
found C 53.15, H 6.15, N 6.17.
49.72, H 6.11, N 6.43.
Eur. J. Inorg. Chem. 2009, 1989–1999
© 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
www.eurjic.org
1997